Evidence map›Paper›PMID 30744320›Full record

ArticleCancer research and treatment2019

Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database.

Jae Seung Lee, In Rae Cho, Hye Won Lee, Mi Young Jeon, Tae Seop Lim, Oidov Baatarkhuu, Do Young Kim, Kwang-Hyub Han, Jun Yong Park

Open access · diamondAbstract read
In one paragraph

Article in Cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jae Seung LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
In Rae ChoDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Hye Won LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Mi Young JeonDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Tae Seop LimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Oidov BaatarkhuuDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Do Young KimDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Kwang-Hyub HanDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Jun Yong ParkDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Severance Hospital · KRYonsei University · KRKorean Cancer Study Group · KR

Funding

Korea Health Industry Development InstituteMinistry of Health and WelfareMinistry of Health and Welfare HI15C2859National Research Foundation of Korea 2018R1A2B20-05901
6 · The paper itself

Abstract

purposeConditional survival estimates (CSE) can provide additional useful prognostic information on the period of survival after diagnosis, which helps in counseling patients with cancer on their individual prognoses. This study aimed to analyze conditional survival (CS) for hepatocellular carcinoma (HCC) using a Korean national registry. MATERIALS AND

methodsPatients with HCC, registered in the Korean cancer registry database, were retrospectively reviewed. Overall survival (OS) was calculated using the Kaplan-Meier method. The 1-year CS at X year or month after diagnosis were calculated as CS1=OS(X+1)/OS(X). CS calculations were performed in each Barcelona Clinic Liver Cancer stage, after which patients at stage 0, A, and B underwent subgroup analysis using initial treatment methods.

resultsA total of 4,063 patients diagnosed with HCC from January 2008 to December 2010, and 2,721 who were diagnosed from January 2011 to December 2012, were separately reviewed. In 2008-2010, the 1-year CS of 1, 2, 3, 4, and 5-year survivors was 82.9%, 85.1%, 88.3%, 88.0%, and 88.6%, respectively. Patients demonstrated an increase in CSE over time in subgroup analysis, especially in the advanced stages. In 2011-2012, the 1-year CS of 6, 12, 18, 24, 30, and 36 months was 81.5%, 83.8%, 85.3%, 85.5%, 86.5%, and 88.8%, respectively. The subgroup analysis showed the same tendency towards increased CSE in the advanced stages.

conclusionOverall, the CS improved with each additional year after diagnosis in both groups. CSE may therefore provide a more accurate prognosis and hopeful message to patients who are surviving with or after treatment.

Indexed as

AgedCarcinoma, HepatocellularDatabases, FactualFemaleHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedPredictive Value of TestsPrognosisRegistriesRepublic of KoreaRetrospective StudiesCarcinomaConditional survival estimateDemographicHepatocellularPrognosisRepublic of KoreaSurvival

Identifiers

PMID30744320
PMCPMC6790830
OpenAlexW2911987651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.